Correction to “Comprehensive analysis of clinical prognosis and biological significance of CNIH4 in cervical cancer” Wang, J, Wang, S, Wang, J, Huang, J, Lu, H, Pan, B, Pan, H, Song, Y, Deng, Q, Jin, X, Shi, G. Comprehensive analysis of clinical prognosis and biological significance of CNIH4 in cervical cancer. Cancer Med. 2023; 12(24): 22381–22394. doi: 10.1002/cam4.6734

IF 2.9 2区医学 Q2 ONCOLOGY

Cancer Medicine Pub Date : 2024-09-08 DOI:10.1002/cam4.70214

引用次数: 0

Abstract

In section 2.7 on page 22383, “Tubulin (1:20000, Proteintech)” should have read “Actin (1:80000, ABclonal).” In Figure 3, Part A, on page 22388, “Tubulin” was incorrect and should have read “Actin.” Please see the corrected figure below. Although we used both Actin and Tubulin as the internal reference genes in the pre-experiment, the statistics of the data show Actin instead of Tubulin.

We apologize for these errors.

Abstract Image

查看原文本刊更多论文

宫颈癌CNIH4临床预后及生物学意义的综合分析》Wang J, Wang S, Wang J, Huang J, Lu H, Pan B, Pan H, Song Y, Deng Q, Jin X, Shi G. 《宫颈癌CNIH4临床预后及生物学意义的综合分析》Correction to "Comprehensive analysis of clinical prognosis and biological significance of CNIH4 in cervical cancer"（《宫颈癌CNIH4临床预后及生物学意义的综合分析》）.Cancer Med.Doi: 10.1002/cam4.6734.

在第 22383 页的第 2.7 节中，"Tubulin（1:20000，Proteintech 公司）"应为 "Actin（1:80000，ABclonal 公司）"。在第 22388 页的图 3 A 部分中，"Tubulin "不正确，应为 "Actin"。请参见下图更正后的内容。虽然我们在实验前同时使用了 Actin 和 Tubulin 作为内参基因，但数据统计中显示的是 Actin 而不是 Tubulin。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.